Calprotect’s founder Alexandru Schiopu has been awarded the “Erik K. Fernström prize” 2021 for younger, particularly promising and successful researchers at the Medical Faculty of Lund University.
Read more here:
Lunds Fernströmspris för forskning som förbättrar behandling av hjärtsjukdom (Swedish)
The findings by the team of Dr. Alexandru Schiopu on the beneficial therapeutic effects of calprotectin blockade in myocardial infarction have been highlighted as one of the most important discoveries of 2019 in coronary artery disease. The study has been included in the yearly European Heart Journal editorial “The year in cardiology: acute coronary syndromes 2019”.
Read the article here:
The year in cardiology: acute coronary syndromes 2019
The research team of Dr. Alexandru Schiopu at Lund University published the first proof-of-concept study showing that short-term blockade of calprotectin (S100A8/A9) with a small molecule therapeutic inhibits inflammation, reduces heart damage and improves heart function in mice with myocardial infarction (MI). The study has been published in the European Heart Journal, the top-ranked international journal in the cardiovascular field.
Read the article here:
Inhibition of inflammation by short-term S100A9 blockade improves cardiac function after myocardial infarction
